Back to All

Trading update

8 July, 2019

Diaceutics PLC (AIM: DXRX), a provider of data analytics and implementation services to the global pharmaceutical industry, announces a trading update for the six months ended 30 June 2019.  Trading has continued in line with market expectations and the Company remains well positioned in key markets, underpinned by a strong sales performance.

An increased international footprint has enhanced Diaceutics’ global offering and allowed the Company to acquire new international clients.  The Nexus project is progressing as planned.

All outstanding debt has now been retired from the balance sheet resulting in net cash of £14.0m.

The Group’s interim results are expected to be announced in early September.

About Diaceutics

At Diaceutics we believe that every patient should get the precision medicine they deserve. We are a data analytics and end-to-end services provider enabled by DXRX - the world’s first Network solution for the development and commercialization of precision medicine diagnostics. 

Diaceutics has worked on every precision medicine brought to market and provides services to 36 of the world’s leading pharmaceutical companies. We have built the world’s largest repository of diagnostic testing data with a growing network of 2500 labs in 51 countries.

Public Relations & Investor Relations advisers

Alma PR
71-73 Carter Lane

Tel: +44 (0)20 3405 0205 or [email protected]

Caroline Forde
Robyn Fisher
Kieran Breheny